CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
Portfolio Pulse from Vandana Singh
The CDC's Advisory Committee on Immunization Practices has recommended expanding the use of pneumococcal vaccines from Merck and Pfizer to adults aged 50 and older. This decision is expected to increase vaccine uptake and reduce the burden of pneumococcal disease.
October 24, 2024 | 6:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The CDC's recommendation to expand the use of Merck's pneumococcal vaccine to adults aged 50 and older could increase demand for the vaccine, potentially boosting Merck's revenues.
The CDC's recommendation is likely to increase the target market for Merck's vaccine, potentially leading to higher sales and revenue. The expanded age group from 65 to 50 years old significantly broadens the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer's pneumococcal vaccine, PREVNAR 20, is set to see increased demand following the CDC's recommendation to expand its use to adults aged 50 and older, which could positively impact Pfizer's sales.
The CDC's expanded recommendation for Pfizer's vaccine increases its potential market size, likely leading to higher sales. The vaccine's coverage of 20 serotypes that cause significant disease burden supports this positive outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80